Arcturus Therapeutics Holdings News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

30.09.24	CSL, Arcturus's Sa-mRNA COVID-19 Vaccine Shows Positive Immune Response; Stock Up (RTTNews)
13.09.24	CSL And Arcturus Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine (RTTNews)
07.06.24	These Biotech Stocks Hit New Highs, Did You Reap The Rewards? (RTTNews)
21.12.23	CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster (PR Newswire)
28.11.23	Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults (PR Newswire)
29.03.23	Pre-market Movers: ARCT, CONN, LULU, JFIN, CARM… (RTTNews)
12.12.22	CSL Seqirus Finalises Exclusive License Agreement With Arcturus' MRNA Technology (RTTNews)
12.12.22	CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics (PR Newswire)
01.11.22	CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology (PR Newswire)
10.08.21	Pre-market Movers: DYNT, ARCT, BHTG, MILE, SDC… (RTTNews)
01.03.21	Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates (Businesswire)
22.02.21	Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals (Businesswire)
19.02.21	Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021 (Businesswire)
11.02.21	Arcturus Therapeutics to Present at Upcoming Investor Conferences (Businesswire)
08.01.21	ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data (RTTNews)
06.01.21	Arcturus Therapeutics to Present at Upcoming Investor Conference (Businesswire)
04.01.21	Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States (Businesswire)
30.12.20	Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease (Businesswire)
29.12.20	Stock Alert: Arcturus Therapeutics Tanks Over 50% (RTTNews)
08.12.20	Pre-market Movers In Healthcare Sector: NURO, CGIX, MRNS, ARCT… (RTTNews)
08.12.20	Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock (Businesswire)
07.12.20	Arcturus Therapeutics Announces Proposed Public Offering of Common Stock (Businesswire)
07.12.20	Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency (Businesswire)
01.12.20	MRNA Faces AdCom On Dec.17, NVAX To Begin Phase 3 COVID Vaccine Trials In US, Mexico, AMGN On Watch (RTTNews)
01.12.20	Arcturus Therapeutics to Present at Upcoming Investor Conference (Businesswire)
09.11.20	Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data (Businesswire)
04.11.20	Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences (Businesswire)
30.10.20	Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020 (Businesswire)
05.10.20	Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency (Businesswire)
01.10.20	Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference (Businesswire)
04.09.20	Arcturus Therapeutics Announces Preclinical Publication Of COVID-19 Vaccine Candidate (RTTNews)
24.08.20	After Market Hours: VivoPower, Arcturus Therapeutics, Tortoise Gain; Liminal, Portland General Slip (RTTNews)
28.07.20	MRNA, PFE/BNTX COVID-19 Vaccines Move Into Phase 3, CytoDyn On Watch, GNCA To Report Data On Jul.30 (RTTNews)
22.07.20	AUPH Faces FDA In Jan, ARCT To Advance LUNAR-COV19 Vaccine, IFRX On Watch, All Eyes On ALEC (RTTNews)
28.05.20	PHAS To Begin COVID-19 Drug Trial In June, MRSN Hits New High, LJPC Plunges, RCUS On Watch (RTTNews)
27.04.20	Stock Alert: Arcturus Shares Up 15% In Premarket (RTTNews)
27.04.20	Arcturus Announces Positive Preclinical Data For COVID-19 Vaccine; Stock Up (RTTNews)
09.04.20	Arcturus To Initiate Human Clinical Trial This Summer For COVID-19 Vaccine (RTTNews)
05.03.20	Stock Alert: ARCT Shares Hit New 52-Week High (RTTNews)
04.03.20	Stock Alert: Arcturus Therapeutics Stock Up 17% In Pre-Market (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Arcturus Therapeutics Holdings Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten